Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 16/20 | 0.47 |
| ▸ | RPS6KB1 | P23443 | 4/20 | 0.41 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.38 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.38 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3210187 | 0.90 | MAPK14 (0.43) | MAPK14RPS6KB1MAPK13MAPK12MAPK11 | |
| SCHEMBL3222738 | 0.90 | MAPK14 (0.48) | MAPK14RPS6KB1MAPK13MAPK12MAPK11 | |
| SCHEMBL3201264 | 0.90 | MAPK14 (0.42) | MAPK14RPS6KB1MAPK13MAPK12MAPK11 | |
| SCHEMBL3212687 | 0.90 | MAPK14 (0.43) | MAPK14RPS6KB1MAPK13MAPK12MAPK11 | |
| SCHEMBL3221037 | 0.90 | MAPK14 (0.47) | MAPK14RPS6KB1MAPK13MAPK12MAPK11 | |
| SCHEMBL3222718 | 0.90 | MAPK14 (0.47) | MAPK14RPS6KB1MAPK13MAPK12MAPK11 | |
| SCHEMBL3209343 | 0.90 | MAPK14 (0.43) | MAPK14RPS6KB1MAPK13MAPK12MAPK11 | |
| SCHEMBL3218578 | 0.89 | MAPK14 (0.42) | MAPK14RPS6KB1 | |
| SCHEMBL3208082 | 0.89 | MAPK14 (0.42) | MAPK14RPS6KB1 | |
| SCHEMBL3214530 | 0.89 | MAPK14 (0.42) | MAPK14RPS6KB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2010019930-A1 | UREA DERIVATIVES AS INHIBITORS OF MAP KINASES | LOCUS PHARMACEUTICALS, INC. (US) | 2010-02-18 | — | — | WO | disclosed |
| US-20100041642-A1 | UREA INHIBITORS OF MAP KINASES | LOCUS PHARMACEUTICALS, INC. (US) | 2010-02-18 | — | — | US | disclosed |
| US-20100041642-A1 | UREA INHIBITORS OF MAP KINASES | LOCUS PHARMACEUTICALS, INC. (US) | 2010-02-18 | — | — | US | disclosed |
| US-20100041642-A1 | UREA INHIBITORS OF MAP KINASES | LOCUS PHARMACEUTICALS, INC. (US) | 2010-02-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100041642-A1 | UREA INHIBITORS OF MAP KINASES | MAP4K2, MAP3K1, MAP3K20 | MAPK14 33/4885RPS6KB1 355/4885MAPK13 44/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.